Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition

ABSTRACT In March 2025, the Japanese Society for Hereditary Tumors and the Ministry of Health, Labour and Welfare (MHLW) Research on Promotion of Cancer Control Program Grant Number JPMH 23EA1037 published the “Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes with Multigene Panel Testing (MGPT), 2025 Edition.” Unlike conventional phenotype‐based guidelines, this guidance promotes preemptive cancer medicine based on genotype. The guidance establishes standardized criteria for MGPT eligibility, emphasizing its utility in both cancer‐affected and cancer‐free individuals to identify actionable germline pathogenic variants (GPVs). Key recommendations include the integration of gene‐specific curation for variant interpretation and the implementation of structured clinical practice systems for risk management. By providing evidence‐based management strategies for 56 cancer‐susceptibility genes, this guidance facilitates the shift toward genotype‐driven oncology. This digest assists healthcare providers in utilizing MGPT and supports shared decision‐making for patients and their relatives.

Authors

Institutions

Publication Details

Journal
Cancer Science
Published
2026-10-24
DOI
https://doi.org/10.1111/cas.70566
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition

Gou Yamamoto, Reiko Yoshida, Kazuhiko Shien, Tomoko Yoshihama et al.
Cancer Science
BRCA gene mutations in cancer
article

Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition

Gou Yamamoto, Reiko Yoshida, Kazuhiko Shien, Tomoko Yoshihama, もも子 荒木, Yoshinaga Okugawa, Katsutoshi Oda, Tomoyuki Aruga, Chikako Tomozawa, Sayaka Ueno, Tomoharu Tokutomi, Naohito Hatta, Fumiharu Miura, Masachika Ikegami, Wataru Yamagami, Kazuhiro Takekoshi, Noriko Tanabe, Masahiko Tanabe, Akiyo Yoshimura, Hiroko Terui-Kohbata, Yusaku Urakawa, Yusuke Ohkuma, Hiroyuki Matsubayashi, Akihiro Sakurai, Yusuke Kobayashi, Manami Matsukawa, Ayaka Sato, Takeshi Makabe, Hisashi Hasumi, Tatsuro Yamaguchi, Tomomi Oka, Junko Kawano, Kunitoshi Shigeyasu, Yasuyuki Miyakura, Masato Yonamine, Arisa Ueki, Kensuke Kumamoto, Hiroyoshi Hattori, Shigenobu Suzuki, Yoshiko Nakano, Yumie Hiraoka, Keika Kaneko, Hirotaka Matsui, 中島 健, Kenta Masuda, Issei Imoto, Megumi Matsumoto, Mashu Futagawa, Akira Hirasawa, Makoto Hirata, Hideki Yamamoto, Shinya Oda, Hideyuki Ishida, Yoshiko Mori, Yasuko Yamamoto, Kazuyuki Oishi, Shunsaku Takayanagi, Hisako Ono, Takeshi Kuwata, Miki Aitani, Hiroko Fujita, Atsushi Watanabe, Nabue Takaiso, Masayoshi Yamada, Yoshiko Nakayama, Kaori Kimura, Kouji Ohta
article en

Abstract

ABSTRACT In March 2025, the Japanese Society for Hereditary Tumors and the Ministry of Health, Labour and Welfare (MHLW) Research on Promotion of Cancer Control Program Grant Number JPMH 23EA1037 published the “Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes with Multigene Panel Testing (MGPT), 2025 Edition.” Unlike conventional phenotype‐based guidelines, this guidance promotes preemptive cancer medicine based on genotype. The guidance establishes standardized criteria for MGPT eligibility, emphasizing its utility in both cancer‐affected and cancer‐free individuals to identify actionable germline pathogenic variants (GPVs). Key recommendations include the integration of gene‐specific curation for variant interpretation and the implementation of structured clinical practice systems for risk management. By providing evidence‐based management strategies for 56 cancer‐susceptibility genes, this guidance facilitates the shift toward genotype‐driven oncology. This digest assists healthcare providers in utilizing MGPT and supports shared decision‐making for patients and their relatives.

Cancer Science
Kanazawa University (JP), Tokyo Medical and Dental University (JP), Kansai Medical University (JP), Shinshu University (JP), Sapporo Medical University (JP), Fujita Health University (JP), University of Tsukuba (JP), Okayama University (JP), Shimane University (JP), Kawasaki Medical School (JP), Kagawa University (JP), Keio University (JP), Hospital for Sick Children (CA), CHI Health (US), Tokyo Metropolitan Komagome Hospital (JP), University of Shimane (JP), St. Luke's International Hospital (JP), Toyama Prefectural Central Hospital (JP), Shizuoka Cancer Center (JP), Fukui Prefectural Hospital (JP), Iwate Prefectural Central Hospital (JP), National Hospital Organization Kyushu Cancer Center (JP), Tokyo Medical Center (JP), Okayama University Hospital (JP), Osaka International Cancer Institute (JP), Kanazawa University Hospital (JP), University of Tokyo Hospital (JP), University of Tsukuba Hospital (JP), Mie University Hospital (JP), Saitama Cancer Center (JP), Tochigi Cancer Center (JP), Saitama International Medical Center (JP), Himeji Red Cross Hospital (JP), Aichi Cancer Center (JP), The Cancer Institute Hospital (JP), National Hospital Organization (JP), Shikoku Cancer Center (JP), National Cancer Center Hospital East (JP), Kyoto University Hospital (JP), Nagoya Medical Center (JP), Institute of Applied Biochemistry (JP), Nagasaki University (JP), Saitama Medical Center, Saitama Medical University (JP), National Cancer Center Hospital (JP), National Cancer Center Research Institute (JP), The University of Tokyo (JP), Saitama Medical University (JP), Yokohama City University (JP)
Openalex Percentile: Top 15%
BRCA gene mutations in cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon